- Report
- April 2025
- 175 Pages
Global
From €3942EUR$4,490USD£3,429GBP
- Report
- September 2025
- 159 Pages
Global
From €5136EUR$5,850USD£4,467GBP
- Report
- September 2025
- 565 Pages
Global
From €6141EUR$6,995USD£5,342GBP
- Report
- January 2025
- 240 Pages
Global
From €2502EUR$2,850USD£2,176GBP
- Report
- May 2025
- 144 Pages
Global
From €2633EUR$2,999USD£2,290GBP
- Report
- April 2025
- 200 Pages
Global
From €3942EUR$4,490USD£3,429GBP
- Report
- August 2025
- 196 Pages
Global
From €3112EUR$3,545USD£2,707GBP
€3458EUR$3,939USD£3,008GBP
- Report
- April 2025
- 175 Pages
Global
From €3942EUR$4,490USD£3,429GBP
- Report
- April 2025
- 200 Pages
Global
From €3942EUR$4,490USD£3,429GBP
- Report
- September 2025
- 573 Pages
Global
From €5136EUR$5,850USD£4,467GBP
- Report
- April 2025
- 225 Pages
Global
From €3951EUR$4,500USD£3,436GBP
- Report
- December 2022
- 280 Pages
Global
From €2107EUR$2,400USD£1,833GBP
- Report
- April 2023
- 177 Pages
Global
From €3665EUR$4,175USD£3,188GBP
- Report
- February 2025
- 139 Pages
China
From €2633EUR$2,999USD£2,290GBP
- Report
- July 2024
- 136 Pages
Global
From €2195EUR$2,500USD£1,909GBP
From €3073EUR$3,500USD£2,673GBP
- Report
- February 2024
- 75 Pages
Asia Pacific
From €4170EUR$4,750USD£3,627GBP
- Report
- February 2024
- 135 Pages
Global
From €4170EUR$4,750USD£3,627GBP
- Report
- February 2024
- 75 Pages
North America
From €4170EUR$4,750USD£3,627GBP
- Report
- April 2023
- 110 Pages
Global
From €4170EUR$4,750USD£3,627GBP

The Presymptomatic Testing market within the context of Genomics is a rapidly growing sector of the healthcare industry. It involves the use of genetic testing to identify individuals who are at risk of developing a particular disease before any symptoms appear. This type of testing can be used to identify genetic mutations that may lead to the development of a disease, allowing for early intervention and prevention. It can also be used to identify individuals who are at risk of passing on a genetic disorder to their children.
Presymptomatic testing is becoming increasingly popular as it allows for early detection and treatment of diseases, which can improve patient outcomes and reduce healthcare costs. It is also being used to identify individuals who may be at risk of developing certain types of cancer.
Companies in the Presymptomatic Testing market include 23andMe, Color Genomics, Invitae, Counsyl, and Myriad Genetics. Show Less Read more